• NEBANNER

China Manufacturer for Bonding Between Glass - 4-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamin; – JIN DUN

China Manufacturer for Bonding Between Glass - 4-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamin; – JIN DUN

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

Using a complete scientific top quality management program, great high-quality and fantastic religion, we win great track record and occupied this area for Ester Content, Silicon Curable Resin, Wastewater Aeration, Our main objectives are to provide our customers worldwide with good quality, competitive price, satisfied delivery and excellent services.
China Manufacturer for Bonding Between Glass - 4-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamin; – JIN DUN Detail:

It works by stimulating central presynaptic alpha 2- receptors. Its hypotensive effect is similar to that of nifedipine, a calcium antagonist, and captopril, an ACE inhibitor. For essential hypertension.

This product should adopt the principle of individualized medication. Generally start from the lowest dose, that is, 0.2mg, once a day, taken in the morning. Dosage adjustments should be made at three-week intervals until satisfactory results are obtained. The usual dose is 0.2mg once, twice a day (morning and evening). The maximum dose per time shall not exceed 0.4mg, and the maximum daily dose shall not exceed 0.6mg. For patients with mild or moderate renal insufficiency, the single dose should not exceed 0.2 mg or the daily dose should not exceed 0.4 mg.

This product is an α2-receptor agonist, which is an imidazoline antihypertensive drug. Used for moderate and severe primary and secondary hypertension.

Because it inhibits the secretion and movement of the gastrointestinal tract, it is also suitable for hypertensive patients suffering from ulcer disease. The combination of this medicine and diuretics can significantly improve the efficacy. It is a powerful central antihypertensive drug and a second-line antihypertensive drug. It is mainly administered locally in ophthalmology. This product has the effect of reducing intraocular pressure, and does not affect the pupil and eye adjustment mechanism. It can constrict blood vessels in the eye, reduce the production of aqueous humor, and achieve the effect of reducing intraocular pressure. It starts to take effect 15 minutes after the eye drops and can maintain the effect for about 8 hours.

Standard:EP10
Assay content:97.5-102.0%

Exterior: White or almost while powder
Package: 1kg/bag or as required by customers


Product detail pictures:

China Manufacturer for Bonding Between Glass - 4-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamin; – JIN DUN detail pictures


Related Product Guide:

Normally customer-oriented, and it's our ultimate concentrate on for being not only one of the most dependable, trustable and honest supplier, but also the partner for our shoppers for China Manufacturer for Bonding Between Glass - 4-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamin; – JIN DUN , The product will supply to all over the world, such as: Greece, Macedonia, Paris, We believe that good business relationships will lead to mutual benefits and improvement for both parties. We have established long-term and successful cooperative relationships with many customers through their confidence in our customized services and integrity in doing business. We also enjoy a high reputation through our good performance. Better performance will be expected as our principle of integrity. Devotion and Steadiness will remain as ever.
  • The after-sale warranty service is timely and thoughtful, encounter problems can be resolved very quickly, we feel reliable and secure.
    5 Stars By Lauren from Cancun - 2018.12.05 13:53
    The sales person is professional and responsible, warm and polite, we had a pleasant conversation and no language barriers on communication.
    5 Stars By ron gravatt from Accra - 2017.06.25 12:48
    Write your message here and send it to us